ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 66 for:    "cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy" OR "Cerebral Arterial Diseases"

Use Lay Language. CAA-ri : a Series of 28 Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03187886
Recruitment Status : Terminated
First Posted : June 15, 2017
Last Update Posted : December 5, 2017
Sponsor:
Collaborators:
Nimes University Hospital
University Hospital, Toulouse
Perpignan Hospital
Beziers Hospital
Narbonne Hospital
Information provided by (Responsible Party):
University Hospital, Montpellier

Brief Summary:

INTRODUCTION: Cerebral amyloid angiopathy-related inflammation (CAA-ri) is a very rare manifestation of cerebral amyloid angiopathy, characterized by acute/subacute neurological deterioration and T2/FLAIR corticosubcortical or deep white matter hyperintensity. With the advent of new diagnostic criteria, there are more and more case reports and series reported; nevertheless, MRI findings and follow-up data need to be thoroughly described.

OBJECTIVES: Our aim in this multicentrical and retrospective study was to describe the clinical and radiological features of patients with CAA-ri and assess long-term prognosis.

METHODS: We reviewed the characteristics of 28 patients with CAA-ri including clinical data, systematic MRI analysis, cerebrospinal fluid results (including Alzheimer's disease biomarkers) and APOE genotype.

HYPOTHESIS: We aimed at describing the clinical and radiological characteristics of a cohort of patients with CAA-ri.


Condition or disease
Cerebral Amyloid Angiopathy Related Inflammation

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 28 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A Clinico-radiological Reappraisal of Cerebral Amyloid Angiopathy-related Inflammation in a Series of 28 Patients.
Actual Study Start Date : January 1, 2017
Actual Primary Completion Date : June 12, 2017
Actual Study Completion Date : July 31, 2017





Primary Outcome Measures :
  1. MRI results [ Time Frame: 1 day ]
    MRI results and Follow-up



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
cerebral amyloid angiopathy related inflammation
Criteria

Inclusion Criteria:

  • Presence of possible or probable amyloid angiopathy according to the most recent diagnostic criteria (Auriel et al., 2016) Or
  • Presence of amyloid angiopathy with perivascular inflammatory infiltrate not meeting the criteria for inflammatory amyloid angiopathy cited above.

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03187886


Sponsors and Collaborators
University Hospital, Montpellier
Nimes University Hospital
University Hospital, Toulouse
Perpignan Hospital
Beziers Hospital
Narbonne Hospital
Investigators
Principal Investigator: Xavier AYRIGNAC, MD University Hospital, Montpellier

Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT03187886     History of Changes
Other Study ID Numbers: RECHMPL17_0149
First Posted: June 15, 2017    Key Record Dates
Last Update Posted: December 5, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: NC

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University Hospital, Montpellier:
Cerebral amyloid angiopathy
CAA-RI
MRI
Intracerebral hemorrhage

Additional relevant MeSH terms:
Cerebral Arterial Diseases
Inflammation
Amyloidosis
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy, Familial
Pathologic Processes
Proteostasis Deficiencies
Metabolic Diseases
Intracranial Arterial Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Cerebral Small Vessel Diseases
Amyloidosis, Familial
Metabolism, Inborn Errors
Genetic Diseases, Inborn